Previous line identifier is [pl]
Instrument previous line refers to any anticancer treatment received, either for a prior cancer or for the current cancer, before the current line.
The current line is the most recently administered one that contains immune checkpoint inhibitors. It can be ongoing at the time of index cardiotoxicity, or may have been interrupted.
Non-ICI anticancer treatments are grouped by pharmacological class and all are attributed a 4-character abbreviation (e.g.
cl_anth_ambi refers to a current line use of anthracycline ambirubicin). For drugs out of the list, there is an “other” section, with abbreviation
othr, followed by a freetext variable.
|Immune checkpoint inhibitors|
Standardized 4-character abbreviations of immune checkpoint inhibitors
Atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, ipilimumab, pembrolizumab, tremelimumab
When drug name is not know, standardized abbreviations related to ICI class.
Anti-PD1, anti-PD-L1, anti-CTLA4
|Other anticancer treatments|
|vegf||Vascular Endothelial Growth Factor inhibitors|
|btki||Bruton Tyrosin Kinase inhibitors|
|rafm||RAF or MEK inhibitors|
|egfr||Endothelial Growth Factor Receptor inhibitors|
|cell||Cell Therapies (mostly CAR-T Cells)|
|immd||Immunomodulators, other than Immune Checkpoint Inhibitors and Cell Therapies|